Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
370
-
Total 13F shares, excl. options
-
96.4M
-
Shares change
-
+9.44M
-
Total reported value, excl. options
-
$6.6B
-
Value change
-
+$646M
-
Put/Call ratio
-
0.93
-
Number of buys
-
214
-
Number of sells
-
-162
-
Price
-
$68.49
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2024
438 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2024.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 370 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96.4M shares
of 108M outstanding shares and own 89.4% of the company stock.
Largest 10 shareholders include FMR LLC (11.2M shares), VANGUARD GROUP INC (9.61M shares), BlackRock Inc. (6.32M shares), WASATCH ADVISORS LP (3.72M shares), JPMORGAN CHASE & CO (3.44M shares), Avoro Capital Advisors LLC (3M shares), Invesco Ltd. (2.94M shares), Bellevue Group AG (2.47M shares), NORGES BANK (1.94M shares), and STATE STREET CORP (1.8M shares).
This table shows the top 370 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.